Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials

Cancer science, 2021-06, Vol.112 (6), p.2381-2392 [Peer Reviewed Journal]

2021 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. ;2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. ;COPYRIGHT 2021 John Wiley & Sons, Inc. ;2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1347-9032 ;EISSN: 1349-7006 ;DOI: 10.1111/cas.14877 ;PMID: 33686753

Full text available